Lutetium oxodotreotide (177Lu-Dotatate) for the treatment of unresectable or metastatic progressive gastroenteropancreatic neuroendocrine tumors: a cost-effectiveness analysis for Scotland

Table 6 Summary cost-effectiveness findings in patients with P-NET

Analysis	¹⁷⁷Lu-Dotatate	Comparator	Δ
P-NET, versus octreotide LAR 60 mg^a
Total costs, GBP	117,922	52,470	65,452
Quality-adjusted life years, QALYs	4.78	2.16	2.61
ICER, GBP per QALY gained		25,068
P-NET versus sunitinib
Total costs, GBP	113,423	81,303	32,119
Quality-adjusted life expectancy, QALYs	4.88	2.92	1.96
ICER, GBP per QALY gained		16,390
P-NET versus everolimus
Total costs, GBP	108,445	70,974	37,472
Quality-adjusted life expectancy, QALYs	4.12	2.69	1.44
ICER, GBP per QALY gained		26,103

^aBased on MAIC data obtained from the placebo arm of the A6181111 trial of sunitinib [17]
GI-NET gastrointestinal neuroendocrine tumor, ICER incremental cost-effectiveness ratio, LAR long-acting release, MAIC matched adjusted indirect comparison, P-NET pancreatic neuroendocrine tumor, QALY quality-adjusted life year
Numerical discrepancies due to rounding

ISSN: 1471-2407